Skip to content

Study · Not a test of the peptide alone · 1992

1 result

Equine leukocyte elastase inhibitor. Primary structure and identification as a thymosin-binding protein.

Dubin A, Travis J, Enghild JJ, Potempa J

The Journal of biological chemistry1 Apr 1992Cited by 30 (Europe PMC)

PMID1551869 (opens in a new tab)DOI10.1016/s0021-9258(19)50466-5 (opens in a new tab)PepBankPUB-01551869
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The primary structure of an elastase inhibitor located in the cytoplasm of leukocytes obtained from the equine species has been determined. By sequence comparison, the protein was found to be a member of the serpin family with strong identity to plasminogen activator inhibitor-2. In contrast to other serpins this protein contained no carbohydrate and had a blocked amino terminus. Preliminary evidence indicates that the inhibitor has the additional feature of being a thymosin beta 4-binding protein, since this polypeptide was always located in purified preparations of the protein. This suggests a physiological role for cytoplasmic elastase inhibitors in the thymosin beta 4-regulated rearrangement of the cytoskeleton of leukocytes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    Preliminary evidence indicates that equine leukocyte elastase inhibitor is a thymosin beta‑4-binding protein, because thymosin beta‑4 was always found in purified preparations of the inhibitor.

    In plain wordsIn lab preparations from horse white blood cells, an elastase inhibitor protein appears to bind thymosin beta‑4. The evidence is preliminary.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableThymosin beta 4 binding by equine leukocyte elastase inhibitor
    Study

    horsen: not reported in source

    Purified equine leukocyte elastase inhibitor preparations
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    Preliminary evidence indicates that the inhibitor has the additional feature of being a thymosin beta 4-binding protein, since this polypeptide was always located in purified preparations of the protein.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.